[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461750":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":24,"responsibleParty":45,"collaborators":18,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":18,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":27,"whyStopped":18,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MitraClip + Optimal medical therapy","EXPERIMENTAL","Patients randomized to this arm will receive percutaneous treatment of secondary mitral regurgitation by MitraClip system and Optimal medical therapy (OMT) for heart failure",[13],"Device: MitraClip",{"label":15,"type":16,"description":17,"interventionNames":18},"Optimal medical therapy","NO_INTERVENTION","Patients randomized to this arm will receive only Optimal medical therapy (OMT) for heart failure",null,[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":18},"DEVICE","MitraClip",[9],[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Marianna Adamo","RECRUITING","Brescia","Lombardy","25123","Italy","IT",{"type":34,"coordinates":35},"Point",[36,37],10.21472,45.53558,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":43,"phoneExt":18,"email":44},"Marianna Adamo, MD","CONTACT","+393897834503","mariannaadamo@hotmail.com",{"type":46,"investigatorFullName":26,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Principal investigator","100461750","mitral-regurgitation-treatment-in-advanced-heart-failure-100461750",false,"NCT05292716","Mitral Regurgitation Treatment in Advanced Heart Failure","MITRADVANCE","Inclusion Criteria:\n\n* Age between 18 and 90 years\n* Significant secondary mitral regurgitation (effective regurgitant orifice area ≥ 5 30mm2) confirmed at the end of the screening period\n* Optimal medical therapy (OMT) according to recent guidelines.\n* Advanced heart failure defined as the presence of all the following criteria, despite OMT:\n\n  * Severe and persistent symptoms of HF (NYHA class III or IV)\n  * Severe cardiac dysfunction defined by a reduced left ventricular ejection fraction (LVEF) ≤35% and\u002For high BNP or NTproBNP levels (BNP\\>125 pg\u002Fml or NTproBNP\\>400 pg\u002Fml if sinus rhythm; BNP\\>375 pg\u002Fml or NTproBNP\\>1200 pg\u002Fml if atrial fibrillation)\n  * Impairment of quality of life (KCCQ \\\u003C 75 points) AND severe impairment of exercise capacity with inability to exercise or low 6MWT distance (\\\u003C450 meters) or pVO2 (\\\u003C14 mL\u002Fkg\u002Fmin or \\\u003C50% of predicted) OR at least 1 unplanned visit or hospitalization in the last 12 months, due to HF, and requiring intravenous diuretics and\u002For inotropes.\n\nExclusion Criteria:\n\n* Unfavorable mitral valve anatomy, which implanting investigator judges as not successfully treatable by the MitraClip (i.e. mitral valve area \\\u003C3 mm2, leaflet length \\\u003C7 mm)\n* Echocardiographic evidence of intracardiac mass, thrombus or vegetation\n* Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated)\n* Active infections requiring current antibiotic therapy\n* Transesophageal echocardiography (TEE) contraindicated or at high risk\n* Untreated significant coronary artery disease requiring revascularization\n* Iron deficiency defined as serum ferritin \\\u003C100 μg\u002FL, or ferritin between 100-299 μg\u002FL and transferrin saturation \\\u003C20% and\u002For intravenous ferric carboxymaltose administration during the 30 days before randomization\n* Coronary artery bypass graft, percutaneous coronary intervention, transcatheter aortic valve replacement or cardiac resynchronization therapy within the prior 30 days\n* Pulmonary vein ablation or cardioversion leading to restore of sinus rhythm or AV node ablation in the last 30 days\n* Myocardial infarction or cerebrovascular accident within prior 30 days\n* Hemodynamic instability defined as systolic blood pressure \\\u003C 90mmHg and cardiogenic shock or need for inotropic support or intra-aortic balloon pump or other hemodynamic support device.\n* Chronic obstructive pulmonary disease, malignancy, or other comorbidities as the main cause of severe symptoms and impaired quality of life.\n* Life expectancy \\\u003C12 months due to non-cardiac conditions","ALL","18 Years","90 Years",{"count":59,"type":60},172,"ESTIMATED","INTERVENTIONAL",[63],"NA","MITRADVANCE-HF is a prospective, randomized, parallel-controlled, open-label, multicentre study trial enrolling patients with SMR and advanced HF on maximally tolerated standard of care therapies for HF according to the most recent guidelines. Enrolled patients will be randomly assigned, in a 1:1 ratio, to a device arm consisting of MitraClip therapy added to optimal medical therapy (OMT) or a control arm of OMT alone. Approximately 20 Italian high-volume centres will be involved. Enrolment duration will be of 24 months. Follow-up visit will be performed at 3, 6, and 12 months. Primary end-point was the absolute change in overall KCCQ summary score (KCCQ-OS) from baseline to 3 months follow-up.",[66,67],"Heart Failure","Mitral Regurgitation",[66,67,22,15],"2024-08-01",{"date":71,"type":72},"2024-08-05","ACTUAL",{"date":74,"type":72},"2021-04-21",{"date":76,"type":60},"2026-04-21",{"name":5,"class":6},1]